Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.140
+0.020 (1.79%)
May 28, 2026, 3:54 PM EDT - Market open
Cocrystal Pharma Revenue
Cocrystal Pharma had revenue of $225.00K in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $225.00K.
Revenue (ttm)
$225.00K
Revenue Growth
n/a
P/S Ratio
68.63
Revenue / Employee
$22,500
Employees
10
Market Cap
15.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 2.01M | -4.55M | -69.32% |
| Dec 31, 2019 | 6.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 78.00K | 69.00K | 766.67% |
| Dec 31, 2014 | 9.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 12.61M | -2.65M | -17.36% |
| Dec 31, 2010 | 15.25M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| HCW Biologics | 6.59M |
| OSR Holdings | 2.63M |
| SeaStar Medical Holding | 1.44M |
| Lexaria Bioscience | 368.00K |
| Vyome Holdings | 152.72K |
COCP News
- 2 days ago - Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses - TheFly
- 2 days ago - Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewsWire
- 13 days ago - Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 27 days ago - Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - GlobeNewsWire
- 4 weeks ago - Cocrystal Pharma files $150M mixed securities shelf - TheFly
- 2 months ago - Cocrystal Pharma receives FDA Fast Track designation for CDI-988 - TheFly
- 2 months ago - Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewsWire
- 2 months ago - Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire